Relationship between the Inflammatory Molecular Profile of Breast Carcinomas and Distant Metastasis Development

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Eiró, Noemí ^a   González, Lucía ^a   González, Luis O ^a   Fernandez Garcia, Belen ^a   Lamelas, Maria Luz ^a   Marín, Laura ^a   González Reyes, Salomé ^a   de Casar, José Manuell ^a   Vizoso, Francisco J ^a  

^a HOSPITAL DE JOVE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

A DESINTEGRIN AND METALLOPROTEASE 15; A DESINTEGRIN AND METALLOPROTEASE 23; A DESINTEGRIN AND METALLOPROTEASE 8; ADAM METALLOPROTEASE WITH THROMBOSPONDIN TYPE 15; ADAM METALLOPROTEASE WITH THROMBOSPONDIN TYPE 2; ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAMTS1 PROTEIN; BETA INTERFERON; CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CLAUDIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 17; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LIPOCORTIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYELOID DIFFERENTIATION FACTOR 88; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MONONUCLEAR INFLAMMATORY CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ADAM PROTEINS; ANNEXIN A2; BREAST NEOPLASMS; CARCINOMA; CHEMOKINE CCL3; CLAUDIN-3; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTERFERON-BETA; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 11; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM METASTASIS; NF-KAPPA B; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 84869010399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049047     Document Type: Article

References (34)

1. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
2. Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, et al. (2007) Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 97: 957-963.
3. Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, et al. (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96: 903-911.
4. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
5. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, et al. (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274: 6935-6945.
6. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, et al. (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114: 111-118.
7. Stetler-Stevenson WG, (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241.
8. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, et al. (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161: 6845-6852.
9. Jiang Y, Goldberg ID, Shi YE, (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245-2252.
10. Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, et al. (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12: 215-227.
11. Ellis IO EC (2006) Histologic grade. ÒMalley FP, Pinder SE: Breast Pathology. 225-233.
12. Allred DC, Harvey JM, Berardo M, Clark GM, (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168.
13. Gonzalez LO, Corte MD, Junquera S, Gonzalez-Fernandez R, del Casar JM, et al. (2009) Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol 40: 1224-1233.
14. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
15. Lin EY, Pollard JW, (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90: 2053-2058.
16. Pollard JW, (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
17. Daniel D, Chiu C, Giraudo E, Inoue M, Mizzen LA, et al. (2005) CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 65: 2018-2025.
18. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, et al. (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470: 548-553.
19. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, et al. (2002) Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 169: 469-475.
20. Salven P, Hattori K, Heissig B, Rafii S, (2002) Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 16: 1471-1473.
21. Gemma A, Takenaka K, Hosoya Y, Matuda K, Seike M, et al. (2001) Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 37: 1554-1561.
22. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, et al. (1997) Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 74: 492-501.
23. Knupfer H, Schmidt R, Stanitz D, Brauckhoff M, Schonfelder M, et al. (2004) CYP2C and IL-6 expression in breast cancer. Breast 13: 28-34.
24. Ueno T, Toi M, Saji H, Muta M, Bando H, et al. (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6: 3282-3289.
25. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, et al. (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88: 1721-1726.
26. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, et al. (2001) Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 282: 735-738.
27. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
28. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121.
29. Weaver CT, Hatton RD, Mangan PR, Harrington LE, (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852.
30. Heng B, Glenn WK, Ye Y, Tran B, Delprado W, et al. (2009) Human papilloma virus is associated with breast cancer. Br J Cancer 101: 1345-1350.
31. Kan CY, Iacopetta BJ, Lawson JS, Whitaker NJ, (2005) Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer 93: 946-948.
32. Lawson JS, Glenn WK, Heng B, Ye Y, Tran B, et al. (2009) Koilocytes indicate a role for human papilloma virus in breast cancer. Br J Cancer 101: 1351-1356.
33. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, et al. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110: 4427-4435.
34. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G, (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621.